These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38901870)

  • 1. Exploring the minimal important difference in the treatment of paediatric obsessive-compulsive disorder using selective serotonin reuptake inhibitors.
    Cohen SE; Denys DAJP; Mattila TK; Storosum BWC; de Boer A; Zantvoord JB
    BMJ Ment Health; 2024 Jun; 27(1):. PubMed ID: 38901870
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic treatment of children and adolescents with obsessive-compulsive disorder.
    Scahill L; Lynch KA
    J Child Adolesc Psychiatr Nurs; 1995; 8(4):36-40. PubMed ID: 8630647
    [No Abstract]   [Full Text] [Related]  

  • 4. Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder.
    Corregiari FM; Bernik M; Cordeiro Q; Vallada H
    Clinics (Sao Paulo); 2012; 67(4):335-40. PubMed ID: 22522758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Drug Ther Bull; 1995 Jun; 33(6):47-8. PubMed ID: 7587998
    [No Abstract]   [Full Text] [Related]  

  • 6. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors.
    Vythilingum B; Cartwright C; Hollander E
    Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S7-13. PubMed ID: 11110014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of treatment response in pediatric obsessive-compulsive disorder.
    Grados MA; Ginsburg GS; Drake KL; Kingery JN
    J Am Acad Child Adolesc Psychiatry; 2009 May; 48(5):573-574. PubMed ID: 19395904
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case series: Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder.
    Owley T; Owley S; Leventhal B; Cook EH
    J Child Adolesc Psychopharmacol; 2002; 12(2):165-71. PubMed ID: 12188985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
    PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy in children and adolescents with obsessive-compulsive disorder.
    Grados M; Scahill L; Riddle MA
    Child Adolesc Psychiatr Clin N Am; 1999 Jul; 8(3):617-34, x. PubMed ID: 10442233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond depression: citalopram for obsessive-compulsive disorder.
    Pato MT
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 2():S19-26. PubMed ID: 10471169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obsessive-compulsive disorder in Tourette syndrome.
    Goodman WK; Storch EA; Geffken GR; Murphy TK
    J Child Neurol; 2006 Aug; 21(8):704-14. PubMed ID: 16970872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Obsessive-compulsive disorder, frontostriatal system and the effect of the serotonergic system].
    Baving L; Schmidt MH
    Z Kinder Jugendpsychiatr Psychother; 2000 Feb; 28(1):35-44. PubMed ID: 10746297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective serotonin reuptake inhibitors in pediatric psychopharmacology: a review of the evidence.
    Hammerness PG; Vivas FM; Geller DA
    J Pediatr; 2006 Feb; 148(2):158-65. PubMed ID: 16492422
    [No Abstract]   [Full Text] [Related]  

  • 18. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
    Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
    Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A longitudinal event-related potential study of selective serotonin reuptake inhibitor therapy in treatment-naïve pediatric obsessive compulsive disorder patients.
    Yamamuro K; Ota T; Iida J; Kishimoto N; Nakanishi Y; Matsuura H; Uratani M; Okazaki K; Kishimoto T
    Psychiatry Res; 2016 Nov; 245():217-223. PubMed ID: 27552672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The first Japanese pediatric case of obsessive-compulsive disorder who responded to a selective serotonin re-uptake inhibitor.
    Furusho J; Kubagawa T; Saitoh N; Matsuzaki K; Yamakawa H; Iikura Y
    Pediatr Int; 2000 Aug; 42(4):451-2. PubMed ID: 10986886
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.